Zydus Lifesciences Limited (ZYDUSLIFE.BO)
INR 859.55
(2.64%)
INR 859.55
(2.64%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 292.8 Billion INR | 13.68% |
| 2023 | 257.56 Billion INR | -7.34% |
| 2022 | 277.95 Billion INR | 16.37% |
| 2021 | 238.84 Billion INR | 0.84% |
| 2020 | 236.86 Billion INR | 0.87% |
| 2019 | 234.83 Billion INR | 29.99% |
| 2018 | 180.65 Billion INR | 18.69% |
| 2017 | 152.2 Billion INR | 44.26% |
| 2016 | 105.5 Billion INR | 15.51% |
| 2015 | 91.34 Billion INR | 14.37% |
| 2014 | 79.86 Billion INR | 8.3% |
| 2013 | 73.74 Billion INR | 14.81% |
| 2012 | 64.23 Billion INR | 39.31% |
| 2011 | 46.1 Billion INR | 23.33% |
| 2010 | 37.38 Billion INR | 11.64% |
| 2009 | 33.48 Billion INR | 30.3% |
| 2008 | 25.69 Billion INR | 27.78% |
| 2007 | 20.11 Billion INR | 27.86% |
| 2006 | 15.73 Billion INR | 15.64% |
| 2005 | 13.6 Billion INR | 1.33% |
| 2004 | 13.42 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 FY | 292.8 Billion INR | 13.68% |
| 2024 Q1 | - INR | -100.0% |
| 2024 Q4 | 292.8 Billion INR | 0.0% |
| 2024 Q3 | - INR | -100.0% |
| 2024 Q2 | 258.79 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 257.56 Billion INR | -7.34% |
| 2023 Q4 | 257.56 Billion INR | 0.0% |
| 2023 Q2 | 256.29 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 277.95 Billion INR | 0.0% |
| 2022 FY | 277.95 Billion INR | 16.37% |
| 2022 Q2 | 274.71 Billion INR | 0.0% |
| 2021 Q2 | 245.5 Billion INR | 0.0% |
| 2021 Q4 | 238.84 Billion INR | 0.0% |
| 2021 FY | 238.84 Billion INR | 0.84% |
| 2020 Q4 | 236.86 Billion INR | 0.0% |
| 2020 FY | 236.86 Billion INR | 0.87% |
| 2020 Q2 | 230.08 Billion INR | 0.0% |
| 2019 Q2 | 180.55 Billion INR | 0.0% |
| 2019 FY | 234.83 Billion INR | 29.99% |
| 2019 Q4 | 234.83 Billion INR | 0.0% |
| 2018 Q2 | 164.94 Billion INR | 0.0% |
| 2018 Q4 | 180.65 Billion INR | 0.0% |
| 2018 FY | 180.65 Billion INR | 18.69% |
| 2017 Q2 | 119.3 Billion INR | 0.0% |
| 2017 FY | 152.2 Billion INR | 44.26% |
| 2017 Q4 | 152.2 Billion INR | 0.0% |
| 2016 Q4 | 105.5 Billion INR | 0.0% |
| 2016 FY | 105.5 Billion INR | 15.51% |
| 2016 Q2 | 97.55 Billion INR | 0.0% |
| 2015 Q2 | 84.73 Billion INR | 0.0% |
| 2015 Q4 | 91.34 Billion INR | 0.0% |
| 2015 FY | 91.34 Billion INR | 14.37% |
| 2014 Q4 | 79.86 Billion INR | 0.0% |
| 2014 Q2 | 79.71 Billion INR | 0.0% |
| 2014 FY | 79.86 Billion INR | 8.3% |
| 2013 FY | 73.74 Billion INR | 14.81% |
| 2013 Q2 | 69.63 Billion INR | 0.0% |
| 2013 Q4 | 73.74 Billion INR | 0.0% |
| 2012 Q4 | 64.23 Billion INR | 0.0% |
| 2012 FY | 64.23 Billion INR | 39.31% |
| 2011 FY | 46.1 Billion INR | 23.33% |
| 2010 FY | 37.38 Billion INR | 11.64% |
| 2009 FY | 33.48 Billion INR | 30.3% |
| 2008 FY | 25.69 Billion INR | 27.78% |
| 2007 FY | 20.11 Billion INR | 27.86% |
| 2006 FY | 15.73 Billion INR | 15.64% |
| 2005 FY | 13.6 Billion INR | 1.33% |
| 2004 FY | 13.42 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | -354.277% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 35.035% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | -927.248% |
| Granules India Limited | 55.2 Billion INR | -430.355% |
| Indoco Remedies Limited | 21.44 Billion INR | -1265.244% |
| Achyut Healthcare Limited | 309.52 Million INR | -94500.061% |
| Ajanta Pharma Limited | 46.38 Billion INR | -531.271% |
| Alkem Laboratories Limited | 155.74 Billion INR | -88.0% |
| Alpa Laboratories Limited | 1.82 Billion INR | -15933.582% |
| Brooks Laboratories Limited | 904.45 Million INR | -32274.007% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -2616.144% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -3726.917% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | -2312.189% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 24.44% |
| Eris Lifesciences Limited | 70.48 Billion INR | -315.399% |
| FDC Limited | 24.68 Billion INR | -1086.375% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | -103.925% |
| Gufic Biosciences Limited | 10.92 Billion INR | -2580.063% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | -2413.144% |
| Ipca Laboratories Limited | 111.01 Billion INR | -163.761% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -13388.608% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -16333.759% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -19308.134% |
| Laurus Labs Limited | 83.87 Billion INR | -249.12% |
| Lupin Limited | 239.97 Billion INR | -22.018% |
| Mankind Pharma Limited | 119.63 Billion INR | -144.756% |
| Medicamen Biotech Limited | 2.94 Billion INR | -9841.791% |
| Medico Remedies Limited | 961.95 Million INR | -30338.909% |
| Megasoft Limited | 3.65 Billion INR | -7902.412% |
| NATCO Pharma Limited | 69.06 Billion INR | -323.972% |
| Piramal Pharma Limited | 153.11 Billion INR | -91.23% |
| RPG Life Sciences Limited | 5.12 Billion INR | -5609.205% |
| Sigachi Industries Limited | 6.94 Billion INR | -4118.184% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 65.739% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | -1199.01% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -7135.832% |
| Unichem Laboratories Limited | 31.69 Billion INR | -823.876% |
| Wanbury Limited | 3.43 Billion INR | -8424.422% |
| Windlas Biotech Limited | 6.26 Billion INR | -4575.905% |
| ZIM Laboratories Limited | 4.46 Billion INR | -6453.12% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -5585.151% |
| Divi's Laboratories Limited | 154.7 Billion INR | -89.275% |
| Hester Biosciences Limited | 6.62 Billion INR | -4320.764% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -3586.087% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -7881.232% |
| Bal Pharma Limited | 3.2 Billion INR | -9039.14% |
| Strides Pharma Science Limited | 58.39 Billion INR | -401.405% |
| Venus Remedies Limited | 6.26 Billion INR | -4571.251% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | -1033.992% |
| Nectar Lifesciences Limited | 21.91 Billion INR | -1236.378% |
| Shilpa Medicare Limited | 30.93 Billion INR | -846.617% |
| Aarti Drugs Limited | 24.32 Billion INR | -1103.802% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | -1204.616% |
| Suven Life Sciences Limited | 2.84 Billion INR | -10177.474% |
| Ind-Swift Limited | 6.54 Billion INR | -4373.962% |
| Valiant Laboratories Limited | 3.42 Billion INR | -8444.466% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | -633.096% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | -1145.483% |
| Themis Medicare Limited | 5.66 Billion INR | -5069.482% |
| Hikal Limited | 24.87 Billion INR | -1077.288% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | -94.415% |
| Sequent Scientific Limited | 15.4 Billion INR | -1800.877% |
| Novartis India Limited | 9.24 Billion INR | -3065.731% |
| Wockhardt Limited | 76.49 Billion INR | -282.806% |
| Jubilant Pharmova Limited | 115.48 Billion INR | -153.546% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -62090.146% |
| Neuland Laboratories Limited | 18.32 Billion INR | -1497.808% |
| Morepen Laboratories Limited | 12.93 Billion INR | -2164.204% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -12097.203% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -8681.846% |